Preparation and use of recombinant influenza a virus m2 constructs and vaccines
CA 2299677 C · Owner: Klimov, Alexander I. · Inventors: Klimov, Alexander I.; Katz, Jacqueline M.; Frace, A. Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide comprising nucleic acids encoding a modified M2 protein of influenza A virus in which transmembrane and other hydrophobic domains have been deleted. The present invention also provides purified polypeptides encoded by the nucleic acids which polypeptides are immunogenic and are less hydrophobic than full-length M2. Also provided are vaccines comprising variants of M2 expressed in prokaryotic hosts. Further provided are methods of preventing influenza A infection using vaccines comprised of variants of M2. Also provided are antibodies raised against the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 6, 1998 and granted July 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 6, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 6, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.